Global Benign Prostatic Hyperplasia BPH Drugs Market Research Report 2023(Status and Outlook)
Report Overview
BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.
North America is the largest consumption place, with a consumption market share nearly 38% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 27.6%. Market competition is intense. Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
The Global Benign Prostatic Hyperplasia BPH Drugs Market Size was estimated at USD 3294.00 million in 2022 and is projected to reach USD 3507.21 million by 2029, exhibiting a CAGR of 0.90% during the forecast period.
Bosson Research’s latest report provides a deep insight into the global Benign Prostatic Hyperplasia BPH Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Benign Prostatic Hyperplasia BPH Drugs Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Benign Prostatic Hyperplasia BPH Drugs market in any manner.
Global Benign Prostatic Hyperplasia BPH Drugs Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Mylan
Novartis
Merck
Market Segmentation (by Type)
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others
Market Segmentation (by Application)
Passenger Vehicle
Commercial Vehicle
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Benign Prostatic Hyperplasia BPH Drugs Market
Overview of the regional outlook of the Benign Prostatic Hyperplasia BPH Drugs Market:
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
- 1 Research Methodology and Statistical Scope
- 1.1 Market Definition and Statistical Scope of Benign Prostatic Hyperplasia BPH Drugs
- 1.2 Key Market Segments
- 1.2.1 Benign Prostatic Hyperplasia BPH Drugs Segment by Type
- 1.2.2 Benign Prostatic Hyperplasia BPH Drugs Segment by Application
- 1.3 Methodology & Sources of Information
- 1.3.1 Research Methodology
- 1.3.2 Research Process
- 1.3.3 Market Breakdown and Data Triangulation
- 1.3.4 Base Year
- 1.3.5 Report Assumptions & Caveats
- 2 Benign Prostatic Hyperplasia BPH Drugs Market Overview
- 2.1 Global Market Overview
- 2.1.1 Global Benign Prostatic Hyperplasia BPH Drugs Market Size (M USD) Estimates and Forecasts (2018-2029)
- 2.1.2 Global Benign Prostatic Hyperplasia BPH Drugs Sales Estimates and Forecasts (2018-2029)
- 2.2 Market Segment Executive Summary
- 2.3 Global Market Size by Region
- 3 Benign Prostatic Hyperplasia BPH Drugs Market Competitive Landscape
- 3.1 Global Benign Prostatic Hyperplasia BPH Drugs Sales by Manufacturers (2018-2023)
- 3.2 Global Benign Prostatic Hyperplasia BPH Drugs Revenue Market Share by Manufacturers (2018-2023)
- 3.3 Benign Prostatic Hyperplasia BPH Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.4 Global Benign Prostatic Hyperplasia BPH Drugs Average Price by Manufacturers (2018-2023)
- 3.5 Manufacturers Benign Prostatic Hyperplasia BPH Drugs Sales Sites, Area Served, Product Type
- 3.6 Benign Prostatic Hyperplasia BPH Drugs Market Competitive Situation and Trends
- 3.6.1 Benign Prostatic Hyperplasia BPH Drugs Market Concentration Rate
- 3.6.2 Global 5 and 10 Largest Benign Prostatic Hyperplasia BPH Drugs Players Market Share by Revenue
- 3.6.3 Mergers & Acquisitions, Expansion
- 4 Benign Prostatic Hyperplasia BPH Drugs Industry Chain Analysis
- 4.1 Benign Prostatic Hyperplasia BPH Drugs Industry Chain Analysis
- 4.2 Market Overview of Key Raw Materials
- 4.3 Midstream Market Analysis
- 4.4 Downstream Customer Analysis
- 5 The Development and Dynamics of Benign Prostatic Hyperplasia BPH Drugs Market
- 5.1 Key Development Trends
- 5.2 Driving Factors
- 5.3 Market Challenges
- 5.4 Market Restraints
- 5.5 Industry News
- 5.5.1 New Product Developments
- 5.5.2 Mergers & Acquisitions
- 5.5.3 Expansions
- 5.5.4 Collaboration/Supply Contracts
- 5.6 Industry Policies
- 6 Benign Prostatic Hyperplasia BPH Drugs Market Segmentation by Type
- 6.1 Evaluation Matrix of Segment Market Development Potential (Type)
- 6.2 Global Benign Prostatic Hyperplasia BPH Drugs Sales Market Share by Type (2018-2023)
- 6.3 Global Benign Prostatic Hyperplasia BPH Drugs Market Size Market Share by Type (2018-2023)
- 6.4 Global Benign Prostatic Hyperplasia BPH Drugs Price by Type (2018-2023)
- 7 Benign Prostatic Hyperplasia BPH Drugs Market Segmentation by Application
- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Benign Prostatic Hyperplasia BPH Drugs Market Sales by Application (2018-2023)
- 7.3 Global Benign Prostatic Hyperplasia BPH Drugs Market Size (M USD) by Application (2018-2023)
- 7.4 Global Benign Prostatic Hyperplasia BPH Drugs Sales Growth Rate by Application (2018-2023)
- 8 Benign Prostatic Hyperplasia BPH Drugs Market Segmentation by Region
- 8.1 Global Benign Prostatic Hyperplasia BPH Drugs Sales by Region
- 8.1.1 Global Benign Prostatic Hyperplasia BPH Drugs Sales by Region
- 8.1.2 Global Benign Prostatic Hyperplasia BPH Drugs Sales Market Share by Region
- 8.2 North America
- 8.2.1 North America Benign Prostatic Hyperplasia BPH Drugs Sales by Country
- 8.2.2 U.S.
- 8.2.3 Canada
- 8.2.4 Mexico
- 8.3 Europe
- 8.3.1 Europe Benign Prostatic Hyperplasia BPH Drugs Sales by Country
- 8.3.2 Germany
- 8.3.3 France
- 8.3.4 U.K.
- 8.3.5 Italy
- 8.3.6 Russia
- 8.4 Asia Pacific
- 8.4.1 Asia Pacific Benign Prostatic Hyperplasia BPH Drugs Sales by Region
- 8.4.2 China
- 8.4.3 Japan
- 8.4.4 South Korea
- 8.4.5 India
- 8.4.6 Southeast Asia
- 8.5 South America
- 8.5.1 South America Benign Prostatic Hyperplasia BPH Drugs Sales by Country
- 8.5.2 Brazil
- 8.5.3 Argentina
- 8.5.4 Columbia
- 8.6 Middle East and Africa
- 8.6.1 Middle East and Africa Benign Prostatic Hyperplasia BPH Drugs Sales by Region
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Egypt
- 8.6.5 Nigeria
- 8.6.6 South Africa
- 9 Key Companies Profile
- 9.1 Eli Lilly
- 9.1.1 Eli Lilly Benign Prostatic Hyperplasia BPH Drugs Basic Information
- 9.1.2 Eli Lilly Benign Prostatic Hyperplasia BPH Drugs Product Overview
- 9.1.3 Eli Lilly Benign Prostatic Hyperplasia BPH Drugs Product Market Performance
- 9.1.4 Eli Lilly Business Overview
- 9.1.5 Eli Lilly Benign Prostatic Hyperplasia BPH Drugs SWOT Analysis
- 9.1.6 Eli Lilly Recent Developments
- 9.2 GlaxoSmithKline
- 9.2.1 GlaxoSmithKline Benign Prostatic Hyperplasia BPH Drugs Basic Information
- 9.2.2 GlaxoSmithKline Benign Prostatic Hyperplasia BPH Drugs Product Overview
- 9.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia BPH Drugs Product Market Performance
- 9.2.4 GlaxoSmithKline Business Overview
- 9.2.5 GlaxoSmithKline Benign Prostatic Hyperplasia BPH Drugs SWOT Analysis
- 9.2.6 GlaxoSmithKline Recent Developments
- 9.3 Astellas Pharma
- 9.3.1 Astellas Pharma Benign Prostatic Hyperplasia BPH Drugs Basic Information
- 9.3.2 Astellas Pharma Benign Prostatic Hyperplasia BPH Drugs Product Overview
- 9.3.3 Astellas Pharma Benign Prostatic Hyperplasia BPH Drugs Product Market Performance
- 9.3.4 Astellas Pharma Business Overview
- 9.3.5 Astellas Pharma Benign Prostatic Hyperplasia BPH Drugs SWOT Analysis
- 9.3.6 Astellas Pharma Recent Developments
- 9.4 Sanofi
- 9.4.1 Sanofi Benign Prostatic Hyperplasia BPH Drugs Basic Information
- 9.4.2 Sanofi Benign Prostatic Hyperplasia BPH Drugs Product Overview
- 9.4.3 Sanofi Benign Prostatic Hyperplasia BPH Drugs Product Market Performance
- 9.4.4 Sanofi Business Overview
- 9.4.5 Sanofi Benign Prostatic Hyperplasia BPH Drugs SWOT Analysis
- 9.4.6 Sanofi Recent Developments
- 9.5 Pfizer
- 9.5.1 Pfizer Benign Prostatic Hyperplasia BPH Drugs Basic Information
- 9.5.2 Pfizer Benign Prostatic Hyperplasia BPH Drugs Product Overview
- 9.5.3 Pfizer Benign Prostatic Hyperplasia BPH Drugs Product Market Performance
- 9.5.4 Pfizer Business Overview
- 9.5.5 Pfizer Benign Prostatic Hyperplasia BPH Drugs SWOT Analysis
- 9.5.6 Pfizer Recent Developments
- 9.6 Abbott
- 9.6.1 Abbott Benign Prostatic Hyperplasia BPH Drugs Basic Information
- 9.6.2 Abbott Benign Prostatic Hyperplasia BPH Drugs Product Overview
- 9.6.3 Abbott Benign Prostatic Hyperplasia BPH Drugs Product Market Performance
- 9.6.4 Abbott Business Overview
- 9.6.5 Abbott Recent Developments
- 9.7 Allergan
- 9.7.1 Allergan Benign Prostatic Hyperplasia BPH Drugs Basic Information
- 9.7.2 Allergan Benign Prostatic Hyperplasia BPH Drugs Product Overview
- 9.7.3 Allergan Benign Prostatic Hyperplasia BPH Drugs Product Market Performance
- 9.7.4 Allergan Business Overview
- 9.7.5 Allergan Recent Developments
- 9.8 TEVA
- 9.8.1 TEVA Benign Prostatic Hyperplasia BPH Drugs Basic Information
- 9.8.2 TEVA Benign Prostatic Hyperplasia BPH Drugs Product Overview
- 9.8.3 TEVA Benign Prostatic Hyperplasia BPH Drugs Product Market Performance
- 9.8.4 TEVA Business Overview
- 9.8.5 TEVA Recent Developments
- 9.9 Mylan
- 9.9.1 Mylan Benign Prostatic Hyperplasia BPH Drugs Basic Information
- 9.9.2 Mylan Benign Prostatic Hyperplasia BPH Drugs Product Overview
- 9.9.3 Mylan Benign Prostatic Hyperplasia BPH Drugs Product Market Performance
- 9.9.4 Mylan Business Overview
- 9.9.5 Mylan Recent Developments
- 9.10 Novartis
- 9.10.1 Novartis Benign Prostatic Hyperplasia BPH Drugs Basic Information
- 9.10.2 Novartis Benign Prostatic Hyperplasia BPH Drugs Product Overview
- 9.10.3 Novartis Benign Prostatic Hyperplasia BPH Drugs Product Market Performance
- 9.10.4 Novartis Business Overview
- 9.10.5 Novartis Recent Developments
- 9.11 Merck
- 9.11.1 Merck Benign Prostatic Hyperplasia BPH Drugs Basic Information
- 9.11.2 Merck Benign Prostatic Hyperplasia BPH Drugs Product Overview
- 9.11.3 Merck Benign Prostatic Hyperplasia BPH Drugs Product Market Performance
- 9.11.4 Merck Business Overview
- 9.11.5 Merck Recent Developments
- 10 Benign Prostatic Hyperplasia BPH Drugs Market Forecast by Region
- 10.1 Global Benign Prostatic Hyperplasia BPH Drugs Market Size Forecast
- 10.2 Global Benign Prostatic Hyperplasia BPH Drugs Market Forecast by Region
- 10.2.1 North America Market Size Forecast by Country
- 10.2.2 Europe Benign Prostatic Hyperplasia BPH Drugs Market Size Forecast by Country
- 10.2.3 Asia Pacific Benign Prostatic Hyperplasia BPH Drugs Market Size Forecast by Region
- 10.2.4 South America Benign Prostatic Hyperplasia BPH Drugs Market Size Forecast by Country
- 10.2.5 Middle East and Africa Forecasted Consumption of Benign Prostatic Hyperplasia BPH Drugs by Country
- 11 Forecast Market by Type and by Application (2024-2029)
- 11.1 Global Benign Prostatic Hyperplasia BPH Drugs Market Forecast by Type (2024-2029)
- 11.1.1 Global Forecasted Sales of Benign Prostatic Hyperplasia BPH Drugs by Type (2024-2029)
- 11.1.2 Global Benign Prostatic Hyperplasia BPH Drugs Market Size Forecast by Type (2024-2029)
- 11.1.3 Global Forecasted Price of Benign Prostatic Hyperplasia BPH Drugs by Type (2024-2029)
- 11.2 Global Benign Prostatic Hyperplasia BPH Drugs Market Forecast by Application (2024-2029)
- 11.2.1 Global Benign Prostatic Hyperplasia BPH Drugs Sales (K MT) Forecast by Application
- 11.2.2 Global Benign Prostatic Hyperplasia BPH Drugs Market Size (M USD) Forecast by Application (2024-2029)
- 12 Conclusion and Key Findings
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook